Device Trial Radar · NCT07843719
Su2ura ESD Closure Pilot Study
Last checked: Nov 19, 2026Latest source record: Sep 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
5
Planned (sponsor's estimate)
Start
Oct 1, 2026
Primary completion
Sep 30, 2027
Study completion Mar 31, 2028
Sponsor
- Lead sponsor
- Chinese University of Hong KongAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 28, 2026
Design
- Study type
- Interventional
- Phase
- Not applicable (typical for device studies)
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Device feasibility
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single-center, prospective, single-arm, non-blinded first-in-human (FIH) early feasibility study intended to evaluate the short-term safety and technical feasibility of closure of gastric post-ESD defects using a novel through-the-scope full-thickness endoscopic suturing system in initial human use. The subjects shall be patients scheduled to undergo ESD for gastric epithelial lesions at the study site (Prince of Wales Hospital) in Hong Kong who meet the eligibility criteria for this study and from whom written informed consent has been obtained. For the gastric defects created after completion of ESD, closure will be attempted using the study device, and its safety, technical success, and early postoperative maintenance of closure will be evaluated. The target sample size of this study shall be 5 cases, and no control group shall be established. No comparison with existing defect closure techniques or verification of superiority will be performed. From the viewpoint of patient protection, comparatively controllable gastric post-ESD defects are selected as the entry model, and the safety signal and basic technical success of this device in its initial human use will be evaluated descriptively. The device specifications used in this study shall remain fixed throughout the study period. During the registration period of the initial cohort of 5 cases, no major changes shall be made to the device itself, accessory equipment, procedural concept, or primary evaluation methods. If device improvement or procedural modification becomes necessary during the study, it shall be handled separately from this initial cohort after obtaining approval from the ethics committee and other relevant authorities, as necessary.
Conditions
- ESD Defect
- Gastric Epithelial Lesion
Interventions
Su2ura® GI systemDevice
The Su2ura® O System is a sterile single-use system intended for endoscopic full-thickness approximation of soft tissue through commonly used endoscopic working channels in both the upper and lower gastrointestinal tract. The system comprises of 3 sterile single-use parts; (1) a flexible endoscopic suturing device (Su2ura® O Device), (2) magazine pre-loaded with up to 6 threaded (0.30mm UHMWPE Braided Cord) nitinol T-Anchors and (3) a suture lock and thread cutting mechanism (Su2ura® Knot Device); the system is planned to be used through a commonly used endoscopic working channels. Each anchor is deployed by a single trigger operation. The sutures are aimed to be 'full-thickness' and are achieved using threaded nitinol T-anchors with a reduced friction mechanism, which enables fast tightening. The sutures are designed to be widely used by any interventional endoscopists in all endoscopic suites for procedures performed in both the upper and lower gastrointestinal tract.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of device-related adverse eventsTime frame: 30 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.